TNFRSF18 and neoplasm: Attention was initially drawn to GITR as a new marker for CD4+CD25+ regulatory T cells (Tregs), essential for the control of a variety of immune responses (autoantigens, infectious and tumor antigens, allergens and alloantigens) [2], [3] which constitutively express high levels of the molecule [1], [4].